IX Biopharma is a Singapore-based specialty pharmaceutical company developing and commercializing medicines using its WaferiX fast-dissolving sublingual wafer drug-delivery technology. It has focused particularly on pain-management and central-nervous-system products, serving patients and healthcare providers through pharmaceutical products such as Wafermine.
Subscribe to see IX Biopharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
IX Biopharma is a pharmaceuticals company headquartered in Singapore. Xcout tracks 9 named people at IX Biopharma, including Janakan Krishnarajah (Chief Operating Officer & Chief Medical Officer).
3 more named people on record for IX Biopharma, with roles, board committees and tenure — see the full roster →
A few of IX Biopharma's closest competitors — see the full list of competitors and alternatives →
Hyphens Pharma International Limited is a Singapore-headquartered pharmaceutical company that develops, licenses, distributes, and markets pharmaceutical and healthcare products. It serves healthcare professionals, hospitals, pharmacies, and consumers across Singapore and other Southeast Asian markets, with a focus on specialty and branded products.
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company’s technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered dissolvable strip. The company is based in Tampa, Florida.
THX Pharma is a biopharmaceutical company that develops therapeutic solutions for rare neurological diseases such as Batten disease, Niemann-Pick type C, and Gaucher disease. The company utilizes antisense oligonucleotides and scientific research to create targeted drug candidates for patients with limited treatment options.
Orexo AB is a pharmaceutical company that specializes in developing innovative drug delivery technologies, notably its powder-based AmorphOX platform. The company advances proprietary and partnered pharmaceutical products, including treatments, vaccines, and nasal delivery formulations, serving patients and healthcare partners globally.
J2 Bio-Pharma, LLC is a specialty pharmaceutical company that reformulates neurology medications to address unmet medical needs. The company partners with pharmacies, patients, and businesses in the healthcare sector to develop and commercialize therapeutic products.
K Pharma, Inc., headquartered in Minato, Japan, was established in 2016 and operates within the Japanese market. The company is dedicated to the research, development, production, and sale of both regenerative medicines and pharmaceutical products. A key focus within their regenerative medicine efforts involves leveraging disease-specific induced pluripotent stem (iPS) cell technology, primarily to develop treatments for conditions such as spinal cord injuries and cerebral infarctions.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.